loading...| Preferred Name |
Carboplatin |
|
| Synonyms |
|
|
| Definitions |
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1282 |
|
| Accepted_Therapeutic_Use_For |
Osteogenic sarcoma; CNS and germ cell tumors; ovarian; lung; head and neck; endometrial; esophageal; bladder; breast; cervical cancer. |
|
| ALT_DEFINITION |
A drug that is used to treat advanced ovarian cancer that has never been treated or symptoms of ovarian cancer that has come back after treatment with other anticancer drugs. It is also used with other drugs to treat advanced, metastatic, or recurrent non-small cell lung cancer and is being studied in the treatment of other types of cancer. Paraplatin is a form of the anticancer drug cisplatin and causes fewer side effects in patients. It attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound. |
|
| CAS_Registry |
41575-94-4 |
|
| CHEBI_ID |
CHEBI:31355 |
|
| Chemical_Formula |
C6H6O4.Pt.2H3N |
|
| code |
C1282 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| definition |
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04) |
|
| Display_Name |
Carboplatin |
|
| FDA_UNII_Code |
BG3F62OND5 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C179531 http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C186341 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C177406 http://purl.obolibrary.org/obo/NCIT_C186327 http://purl.obolibrary.org/obo/NCIT_C186328 http://purl.obolibrary.org/obo/NCIT_C179478 http://purl.obolibrary.org/obo/NCIT_C157711 |
|
| Is_PCDC_GCT_Permissible_Value_For_Variable | ||
| Is_Value_For_GDC_Property | ||
| label |
Carboplatin |
|
| Legacy Concept Name |
Carboplatin |
|
| Maps_To |
Carboplatin |
|
| NCI_Drug_Dictionary_ID |
39176 |
|
| NSC Number |
201345 241240 |
|
| PDQ_Closed_Trial_Search_ID |
39176 |
|
| PDQ_Open_Trial_Search_ID |
39176 |
|
| Preferred_Name |
Carboplatin |
|
| prefixIRI |
NCIT:C1282 |
|
| prefLabel |
Carboplatin |
|
| Semantic_Type |
Pharmacologic Substance Inorganic Chemical |
|
| UMLS_CUI |
C0079083 |
|
| subClassOf |